Therefore, the development of miRNA-based therapies specifically targeting aberrant signaling (AR, PTEN/PI3K/AKT, autophagy signaling, etc.)and/or alternative splicing mechanisms may further lead to novel therapeutics for treatment-resistant PCa. This evidence concerns the gene AR and posterior cortical atrophy.